Literature DB >> 7906654

Anxiolytic-like effects of N-methyl-D-aspartate-associated glycine receptor ligands in the rat potentiated startle test.

E W Anthony1, M E Nevins.   

Abstract

Competitive and non-competitive NMDA receptor complex antagonists have been shown to be active in various models of anxiolytic activity. This study examined the effects of ligands at the NMDA receptor-associated glycine site and two competitive NMDA receptor antagonists on the fear-potentiated startle response model for anxiolytic activity. The results show that the NMDA receptor antagonists, 2-amino-7-phosphonoheptanoate (30 mg/kg) and 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonate (3 mg/kg), the glycine receptor antagonist 7-chlorokynurenate (100 mg/kg), and the glycine receptor partial agonists 3-amino-1-hydroxy-2-pyrrolidinone ((+)-HA-966) (30 mg/kg), 1-aminocyclopropane carboxylate (200-500 mg/kg) and D-cycloserine (30-300 mg/kg) blocked the potentiated startle effect. These results extend the findings of earlier studies showing anxiolytic-like effects of NMDA antagonists and glycine receptor ligands by demonstrating their effectiveness in the rat potentiated startle paradigm. These results also demonstrate the anxiolytic potential of D-cycloserine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7906654     DOI: 10.1016/0014-2999(93)90397-z

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

Review 1.  Animal models of anxiety disorders.

Authors:  Joachim D K Uys; Dan J Stein; Willie M U Daniels; Brian H Harvey
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

2.  Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands.

Authors:  Linda M Rorick-Kehn; John C Hart; David L McKinzie
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

3.  D-cycloserine facilitates extinction of cocaine self-administration in rats.

Authors:  Panayotis K Thanos; Carlos Bermeo; Gene-Jack Wang; Nora D Volkow
Journal:  Synapse       Date:  2011-03-28       Impact factor: 2.562

4.  Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer's disease.

Authors:  Shirley W Y Tsang; Harry V Vinters; Jeffrey L Cummings; Peter T-H Wong; Christopher P L-H Chen; Mitchell K P Lai
Journal:  Neurobiol Aging       Date:  2007-04-11       Impact factor: 4.673

5.  Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats.

Authors:  David L Walker; Kerry J Ressler; Kwok-Tung Lu; Michael Davis
Journal:  J Neurosci       Date:  2002-03-15       Impact factor: 6.167

Review 6.  Rodent Gymnastics: Neurobehavioral Assays in Ischemic Stroke.

Authors:  Sreekala S Nampoothiri; Tanvi Potluri; Harshith Subramanian; Rajanikant G Krishnamurthy
Journal:  Mol Neurobiol       Date:  2016-10-17       Impact factor: 5.590

Review 7.  Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion.

Authors:  Christopher Barkus; Stephen B McHugh; Rolf Sprengel; Peter H Seeburg; J Nicholas P Rawlins; David M Bannerman
Journal:  Eur J Pharmacol       Date:  2009-10-15       Impact factor: 4.432

Review 8.  Innovative approaches for the development of antidepressant drugs: current and future strategies.

Authors:  Lee E Schechter; Robert H Ring; Chad E Beyer; Zoë A Hughes; Xavier Khawaja; Jessica E Malberg; Sharon Rosenzweig-Lipson
Journal:  NeuroRx       Date:  2005-10

9.  D-Cycloserine: Agonist turned antagonist.

Authors:  T H Lanthorn
Journal:  Amino Acids       Date:  1994-10       Impact factor: 3.520

10.  D-Cycloserine and performance under different states of anxiety in healthy volunteers.

Authors:  J E Bailey; A Papadopoulos; A Lingford-Hughes; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  2007-05-18       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.